Tamoxifen-based Treatment Induces Clinically Meaningful Responses in Multiple Myeloma Patients with Relapsing Disease after Autotransplantation

A. B.-T. Fassas Department of Internal Medicine, Bone Marrow Transplant Program, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USACorrespondence[email protected]

A. P. Rapoport Department of Internal Medicine, Bone Marrow Transplant Program, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

J. Bolaňos-Meade Department of Internal Medicine, Bone Marrow Transplant Program, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

C. Shanholtz Department of Internal Medicine, Bone Marrow Transplant Program, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

M. Cottler-Fox Present address: Myeloma and Transplantation Research Center, University of Arkansas, 4301 W. Markham, Little Rock, AR, 77205, USA

G. Tricot Present address: Myeloma and Transplantation Research Center, University of Arkansas, 4301 W. Markham, Little Rock, AR, 77205, USA

Abstract

Tamoxifen has been shown to induce apoptosis in multiple myeloma cell lines and primary myeloma cells. Daily tamoxifen was given to 12 consecutive multiple myeloma patients who either relapsed following autologous stem cell transplantation (11) or had progressive disease on conventional chemotherapy (1). Methotrexate was also given biweekly to enhance the antiangiogenetic effect. Two patients achieved complete remission lasting 8 and 18 months. Two additional patients had stable disease (SD) for 7 and 11 months. All responders were men and the earliest signs of response were seen after approximately 6–8 weeks of treatment. The regimen was very well tolerated. Speculations about a possible mechanism of action of tamoxifen in multiple myeloma are discussed.

Key Words:

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Tamoxifen-based Treatment Induces Clinically Meaningful Responses in Multiple Myeloma Patients with Relapsing Disease after Autotransplantation

Information for

Open access

Opportunities

Help and information

Tamoxifen-based Treatment Induces Clinically Meaningful Responses in Multiple Myeloma Patients with Relapsing Disease after Autotransplantation

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature